(2-氨基噻唑-4-基)乙酸甲酯盐酸盐 | 76629-18-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (2-氨基噻唑-4-基)乙酸甲酯盐酸盐
• 英文名称: methyl 2-amino-4-thiazoleacetate hydrochloride
• 英文别名: methyl 2-aminothiazole-4-acetate hydrochloride；methyl 2-amino-4-thiazoleacetate HCl；Methyl 2-amino-4-thiazoleacetate hydrochloride salt；methyl (2-amino-1,3-thiazol-4-yl)acetate hydrochloride；Methyl 2-(2-amino-1,3-thiazol-3-ium-4-yl)acetate;chloride
• CAS: 76629-18-0
• 化学式: C₆H₈N₂O₂S*ClH
• 分子量: 208.669
• InChiKey: DCLJYTHCPIQKNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.44
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  (2-氨基噻唑-4-基)乙酸甲酯盐酸盐 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.25h， 生成 methyl (2-{[(adamant-1-ylamino)acetyI]amino}-1,3-thiazol-4-yl)acetate
  参考文献：
  名称：

  [EN] HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF FUNGAL INFECTIONS
  [FR] INHIBITEURS D'HISTONE DÉACÉTYLASE POUR LE TRAITEMENT D'INFECTIONS FONGIQUES

  摘要：

  描述了式(I)的桥联化合物，它们的类似物、互变异构体、立体异构体、几何异构体、多晶形态、水合物、溶剂合物、药学上可接受的盐、药物组合物、代谢产物和其前药。该发明涉及用于治疗真菌感染的组合物和方法。这些化合物是选择性HDAC抑制剂，可作为固有的抗真菌化合物或增强其他抗真菌化合物（如唑类药物）的活性。

  公开号：

  WO2011058582A1
• 作为产物：
  描述：

  甲醇 、 2-氨基噻唑-4-乙酸 在 氯化亚砜 作用下， 反应 0.5h， 以99%的产率得到(2-氨基噻唑-4-基)乙酸甲酯盐酸盐
  参考文献：
  名称：

  [EN] HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF FUNGAL INFECTIONS
  [FR] INHIBITEURS D'HISTONE DÉACÉTYLASE POUR LE TRAITEMENT D'INFECTIONS FONGIQUES

  摘要：

  描述了式(I)的桥联化合物，它们的类似物、互变异构体、立体异构体、几何异构体、多晶形态、水合物、溶剂合物、药学上可接受的盐、药物组合物、代谢产物和其前药。该发明涉及用于治疗真菌感染的组合物和方法。这些化合物是选择性HDAC抑制剂，可作为固有的抗真菌化合物或增强其他抗真菌化合物（如唑类药物）的活性。

  公开号：

  WO2011058582A1

文献信息

• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。
• Cyclic compounds linked by a heterocyclic ring useful as inhibitors of
  申请人：The DuPont Merck Pharmaceutical Company

  公开号：US05773411A1

  公开（公告）日：1998-06-30

  This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation. A representative compound of the invention is cyclo-(D-Val-N(Me)Arg-Gly-Asp-\x9b5-aminomethyl!-2-furoate).

  本发明涉及通过杂环环系连接的新颖环状化合物，这些化合物作为血小板糖蛋白IIb/IIIa复合体的拮抗剂具有用途，涉及含有此类环状化合物的药物组合物，以及使用这些化合物抑制血小板聚集的方法。本发明的一个代表性化合物是环-(D-缬氨酸-N(甲基)精氨酸-甘氨酸-天冬氨酸-ε-氨基甲基-2-糠酸酯)。
• [EN] THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS<br/>[FR] DERIVES DE THIAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE VAP-1
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004067521A1

  公开（公告）日：2004-08-12

  A compound of the formula (I): R1-NH-X-Y-Z (I) wherein R1 is acyl; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond, lower alkylene or -COHN-; and Z is a groupe of the formulae (II) or (III) wherein R2 is a specified substituent or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor for preventing or treating a VAP-1associated disease, especially macular edema.

  一种化合物的分子式（I）：R1-NH-X-Y-Z（I），其中R1为酰基；X为可选取代噻唑衍生的双价残基；Y为键，较低的烷基或-COHN-；Z为分子式（II）或（III）中的基团，其中R2为特定的取代基或其药用可接受的盐，用作预防或治疗与血管粘附蛋白-1（VAP-1）相关的疾病的VAP-1抑制剂，特别是黄斑水肿。
• Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo
  作者：Chu-Biao Xue、Matthew E. Voss、David J. Nelson、James J.-W. Duan、Robert J. Cherney、Irina C. Jacobson、Xiaohua He、John Roderick、Lihua Chen、Ronald L. Corbett、Li Wang、Dayton T. Meyer、Kenneth Kennedy、William F. DeGrado、Karl D. Hardman、Christopher A. Teleha、Bruce D. Jaffee、Rui-Qin Liu、Robert A. Copeland、Maryanne B. Covington、David D. Christ、James M. Trzaskos、Robert C. Newton、Ronald L. Magolda、Ruth R. Wexler、Carl P. Decicco

  DOI：10.1021/jm010127e

  日期：2001.8.1

  To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the PI and P2 ' residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1-P2 ' linkers. With an N-methylamide at P3 ', the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-alpha release from LPS-stimulated human whole blood. Further elaboration in the P3 ' -P4 ' area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of less than or equal to 0.2 muM in whole blood assay (WBA). Although the P3 ' area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3 ' was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3 ', an N-methylamide at P4 ' provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 muM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4 ' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC50 = 0.067 muM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K-i values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.
• Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent
  作者：Masahide Odan、Natsuki Ishizuka、Yoshiharu Hiramatsu、Masanao Inagaki、Hiroshi Hashizume、Yasuhiko Fujii、Susumu Mitsumori、Yasuhide Morioka、Masahiko Soga、Masashi Deguchi、Kiyoshi Yasui、Akinori Arimura

  DOI：10.1016/j.bmcl.2012.02.050

  日期：2012.4

  The optimization of a series of 3-carbamoyl 2-pyridone derivatives as CB agonists is reported. These efforts resulted in the discovery of 3-(2-(1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamido)thiazol-4-yl)propanoic acid (21), a potent dual CB1/CB2 agonist without CNS side effects induced by CB1 receptor activation. It exhibited strong inhibition of scratching as a 1.0% acetone solution in the pruritic model. (C) 2012 Elsevier Ltd. All rights reserved.